{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.1","upperLimit":"68.9","value":"58.1"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1"}]}],"title":"Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5"}]}],"title":"Not evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria in Solid Tumours (RECIST v1.1) assessed by MRI or CT: Complete Response (CR): Disappearance of all target and non-target lesions and no new lesions; Partial Response (PR): \\>= 30% decrease in the sum of diameters of Target Lesions (compared to baseline) and no new lesions; Stable disease (SD): Neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; Progressive Disease (PD): \\>= 20% increase in the sum of diameters of TLs and an absolute increase in sum of diameters of \\>=5mm (compared to the previous minimum sum) or progression of NTLs or a new lesion. Not evaluable (NE): TL response is missing and there is no evidence of progression of NTLs and no new lesions. BOR is the best response (by investigator assessment) a patient has achieved where the order of best to worst is CR, PR, SD, PD, NE prior to or at progression and prior to further anti-cancer therapy.","groups":[{"description":"Pre-treated patient cohort in doses 20, 40, 80, 160 and 240mg AZD9291 capsule.","id":"OG000","title":"Dose Escalation"}],"paramType":"NUMBER","populationDescription":"All pre-treated EGFR T790M mutation positive (by central testing) patients who received at least one dose of AZD9291.","reportingStatus":"POSTED","timeFrame":"RECIST tumour assessments every 6 weeks from randomisation until objective disease progression, up to approximately 25 months (at time of analysis)","title":"Best Objective Response (BOR) for Dose Escalation Population","type":"PRIMARY","unitOfMeasure":"% of participants"}